* Chromadex Corp CDXC.OQ CDXC.O is expected to show a
rise in
quarterly revenue when it reports results on May 8 for the
period ending March 31 2024
* The Los Angeles California-based company is expected to
report
a 6.3% increase in revenue to $23.97 million from $22.56 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Chromadex Corp is for a
loss
of 2 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Chromadex
Corp is
$6.40, above its last closing price of $3.80.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.03 -0.03 0.00 Beat 100
Sep. 30 2023 -0.03 -0.03 -0.01 Beat 69.2
Jun. 30 2023 -0.04 -0.04 -0.03 Beat 20
Mar. 31 2023 -0.05 -0.05 -0.03 Beat 37.5
Dec. -0.03 -0.02 -0.02 Met 17.3
31 2022
Jan. 1 0001 -0.06 -0.06 -0.04 Beat 35.5
Jan. 1 0001 -0.08 -0.08 -0.09 Missed -5.9
Mar. 31 2022 -0.09 -0.09 -0.11 Missed -19.6
This summary was machine generated May 7 at 02:01 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)